Relaps / Refrakter T Hücreli Lenfomada Brentuximab Vedotin Monoterapisi- Gerçek Yaşam Verisi

Year 2024, Volume: 6 Issue: 2, 186 - 192, 30.06.2024

Tahir Darcın , Istemi Serın , Mehmet Can Ugur , Omer Ekinci , İpek Yönal Hindilerden , Seval Akpınar , Tuba Hacıbekiroglu , Sinan Demircioğlu , Emine Gulturk , Murat Albayrak , İsmet Aydoğdu , Mehmet Sinan Dal , Mehmet Hilmi Doğu , Sinem Namdaroğlu , Ali Dogan , Meliha Nalçacı , Burhan Turgut , Semih Başcı , Fevzi Altuntaş

https://doi.org/10.52827/hititmedj.1320606

Abstract

Amaç: Brentuksimab vedotin (BV) ile tedavi edilen Relaps /Refrakter (R/R) THL’li hastaların gerçek yaşam verilerini sunmayı amaçladık.
Gereç ve Yöntem: Bu çalışma gözlemsel, çok merkezli, retrospektif bir çalışmadır. Ocak 2014’ten Temmuz 2020’ye kadar Türkiye’deki on üç merkezde yalnızca BV ile tedavi edilen tüm hastaların (n=17) verileri toplandı.
Bulgular: Ortanca yaşı 53 olan 17 hastaya kurtarma kemoterapisi olarak BV verildi. Dokuz (%52,9) hastaya periferik T hücreli lenfoma, diğer türlü sınıflandırılamayan tanısı konurken, 8 (%47,1) hastaya anaplastik büyük T hücreli lenfoma tanısı konuldu. Kohortun ortanca takip süresi 20 aydı. Dokuz (%52,9) hastada tam yanıt, 5 (%29,5) hastada kısmi yanıt, 3 (%17,6) hastada ilerleyici hastalık görüldü. Güvenlik verileri BV bilinen profiliyle tutarlıydı, 2 pnömoni ve 4. dereceli 1 trombositopeniyi içeriyordu. Grubun medyan progresyonsuz sağkalımı 10 aydı. Siklus sayısının BV tedavisine yanıtın üzerinde etkili olduğu değişkenli analiz ile bulundu.
Sonuç: R/R THL’leri olan hastalarda BV olumlu güvenlik profili ile tatmin edici antitümör aktivitesine sahip olduğu görülmektedir.

Keywords

brentuksimab vedotin, nüks, T hücreli lenfoma

Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Abstract

Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice.
Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected.
Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis.
Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.

Keywords

brentuximab vedotin, relapse, T cell lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-2390.
• Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica 2018;103:1191-1197.
• Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Critical Reviews in Oncology/Hematology 2016;99:214-227.
• Oki Y, Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opinion On Biological Therapy 2012;12:623- 632.
• Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opinion On Biological Therapy 2019;19:197-209.
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014;123:3095- 3100.
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology 2007;25:579-586.
• Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology 2017;28:1436-1447.
• Lamarque M, Bossard C, Contejean A, et al. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica 2016;101:103-106.
• Oberic L, Delzor F, Protin C, et al. Brentuximab vedotin in real life, a seven year experience in patients with refractory/ relapsed CD30+ T cell lymphoma. Journal of Oncology Pharmacy Practice 2021;27: 1730-1735.
• Uncu Ulu B, Dal MS, Hindilerden İY, et al. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy 2021;13:1-9.
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016;128:1562-1566.